Clostridium difficile -associated diarrhea (CDAD) recurs in Ç15% -20% of patients after discontinuation of metronidazole or vancomycin therapy. Most recurrences are believed to be endogenous relapses due to the persistence of spores. However, there is evidence that reinfection with a different strain is a cause of recurrence. We report the case of a patient with a history of multiple episodes of C. difficile colitis. The patient, a 56-year-old female, has had 5 years of repeated recurrences, each shortly after discontinuing vancomycin therapy. During the course of these episodes, three isolates were cultured from her stools at different times. These isolates were analyzed for the presence of toxin A and B gene sequences and genotyped by means of arbitrarily primed polymerase chain reaction (AP-PCR). The original two isolates contained the toxin A and B genes, as determined by PCR, and were of the same AP-PCR type. During her last relapse, a C. difficile strain lacking at least a portion of the toxin B gene was isolated. AP-PCR analysis of this isolate showed a different DNA banding pattern from that of the previous isolates. A vancomycin susceptibility assay revealed a slight decrease in vancomycin activity as compared with that against the prior isolate. This case demonstrates two unique features: (1) recurrent infections can be due to reinfections and (2) toxin B mutants can possibly cause CDAD. This study also raises concerns about long-term vancomycin use and the development of resistance of C. difficile to vancomycin.
Toxigenic Clostridium difficile is the most common cause isolated during the course of her recurrent episodes. Some genotypic characteristics of these isolates as well as their susof nosocomial diarrhea. At least two toxins are known to be responsible for the virulence of C. difficile: toxin A, an enteroceptibility to vancomycin are reported herein. toxin, and toxin B, a potent cytotoxin. These toxins act synergistically to cause extensive tissue damage and fluid accumulaCase Report tion [1] . Until recently it was thought that strains either have the genes for these toxins or lack them. A strain lacking at A 56-year-old woman first had problems due to C. difficile least part of the toxin A gene has been described and characterin May 1989. She had received cefadroxil for the treatment of ized [2] . This isolate, C. difficile 8864, has been found to be sinusitis. She had explosive watery diarrhea occurring up to highly virulent in the animal model [3] . 20 times per day. She was treated with vancomycin, and the C. difficile-associated diarrhea (CDAD) recurs in 15%-20% diarrhea resolved but subsequent relapses occurred. The initial of patients after discontinuation of vancomycin and metronidadiagnosis was made on the basis of toxin assays and endoscopic zole treatment. Until recently, it was believed that recurrences proof of pseudomembranes. She had received vancomycin, were endogenous in nature, due to the persistence of spores metronidazole, bacitracin, cholestyramine, and oral lactobacilafter eradication of the vegetative cells with therapy. In the lus, with relapses after initial response. past several years, reinfection with a new strain of C. difficile She was first seen at our center in 1990, at which time she has been described as a cause of recurrent CDAD [4, 5] . O'Neill was treated with vancomycin enemas. She was thought to have et al. studied 10 patients who had apparent relapses and found irritable bowel syndrome. She had been taking maintenance that more than half of the recurrences were due to infection therapy with oral vancomycin at doses between 125 and with a different strain [4] . 500 mg q.i.d. for years. In February 1995 she began having We report the case of a patient with a history of multiple diarrhea again. The cytotoxin assay was once again positive CDAD recurrences, from whom two different strain types were for C. difficile toxin B. Since that time she has had intermittent episodes of diarrhea with C. difficile.
Isolates were identified as C. difficile by the latex agglutination test (Becton Dickinson, Cockeysville, MD). Isolates lacking the toxin B gene were further identified with the Analytical People Index Anaerobic Panel (Analytical Products, Plainview, NY).
Amplification of the Toxin A and B Gene Sequences
The presence of the toxin A and B genes was determined by PCR on all isolates. The primers and conditions for amplification of the toxin A and B genes are described elsewhere [7, 8] . In brief, the reaction mixtures were prepared in 11 PCR buffer (50 mM of KCl, 20 mM of Tris-HCl, 2.5 mM of MgCl 2 , and 100 mg of bovine serum albumin per mL [pH, 8.4]) and contained 20 pmol of each of the primers, 0.1 mM each of deoxynucleoside triphosphates, 2 U of Taq polymerase, and 5 mL of the DNA preparation in each reaction. banding patterns of each isolate were compared by running PCR products on the same gel as described previously [9] .
Vancomycin Susceptibility
C. difficile isolates were tested for susceptibility to vancomycin by means of the Etest (AB BIODISK, Solna, Sweden). The testing was performed as described for anaerobic organisms. Streptococcus pneumoniae ATCC 49619, incubated in 5% -10% CO 2 for Ç24 hours, was used as a control organism.
Results

C. difficile Isolates
Three isolates were cultured from the stool of the patient during a 5-year period. The first two isolates (P-752 [1990] figure 1 ). Genotyping of this strain revealed a
